2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 211

Effects of Deep Haptic Massage in Fibromyalgia (pilot Study)

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 615

Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 207

Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 218

Effects of Tai Chi versus Aerobic Exercise on Mindfulness in Fibromyalgia

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 363

Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 548

Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 506

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 531

Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 512

Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 520

Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 537

Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 277

Efficacy of a Counselling Program to Promote Physical Activity in People with Inflammatory Arthritis

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 519

Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 206

Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 310

Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].